In A Messy Democratic Presidential Debate, Facts About Medicare For All Get Tossed About
Candidates used their varying views on how to achieve universal coverage — whether through Medicare for All or more incremental steps — as a means to differentiate themselves from the field.
Democrats Favor Building On ACA Over ‘Medicare For All’
Asked to choose between building on the Affordable Care Act and replacing it with a national Medicare for All plan, 55% of Democrats and Democratic-leaning independents said they would expand the existing law, according to a Kaiser Family Foundation poll released Tuesday.
GOP Senators Distance Themselves From Grassley And Trump’s Efforts To Cut Drug Prices
Even some Republicans who supported a sweeping bipartisan bill to rein in drug costs may not back it in the Senate vote.
Summer Setbacks: The Long Road To Lower Drug Prices Hits Some Potholes
Efforts to control drug prices seemed on a glide path earlier this year after gaining traction at the White House and in Congress. But prospects today look less certain and highly controversial.
Pelosi Aims For Feds To Negotiate Drug Prices, Even For Private Insurers
A draft plan spearheaded by House Speaker Nancy Pelosi would allow the federal government for the first time to negotiate prices for 250 drugs for Medicare and apply those prices to all payers, including employers and insurers.
Universal Health Care For New Yorkers? Not Exactly
Despite what New York Mayor Bill de Blasio claimed during the first night of the presidential debates, universal health care in the Big Apple is still in the seeding stage.
Trump Administration Rule Would Undo Health Care Protections For LGBTQ Patients
Supporters of the rule say it would strengthen health care professionals’ freedom of conscience, but opponents say it “empowers bad actors to be bad actors.”
FDA Overlooked Red Flags In Drugmaker’s Testing of New Depression Medicine
In March, a chemical cousin of the anesthetic and club drug ketamine was approved for the treatment of patients with intractable depression. But critics say studies presented to the FDA provided at best modest evidence it worked and did not include information about the safety of the drug, Spravato, for long-term use.
Klobuchar Wants To Stop ‘Pay-For-Delay’ Deals That Keep Drug Prices High
It’s as shady as it sounds.
Pharma Execs Dig In For A Fight Against Outraged Senators
The Senate Finance Committee grilled executives from seven major drugmakers on Tuesday.